Published in Mol Pharm on March 26, 2013
Progresses towards safe and efficient gene therapy vectors. Oncotarget (2015) 0.88
Efficient in vitro gene delivery by hybrid biopolymer/virus nanobiovectors. J Control Release (2014) 0.79
Intracellular trafficking of hybrid gene delivery vectors. J Control Release (2015) 0.75
Insights into the nuclear export of murine leukemia virus intron-containing RNA. RNA Biol (2015) 0.75
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 7.58
Design and development of polymers for gene delivery. Nat Rev Drug Discov (2005) 6.79
Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A (1978) 6.55
Gene therapy -- promises, problems and prospects. Nature (1997) 6.02
Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta (1991) 5.09
Single bilayer liposomes prepared without sonication. Biochim Biophys Acta (1973) 3.83
Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem (1994) 3.24
A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun (1991) 2.72
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther (2001) 2.35
Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem J (1980) 1.97
Nonviral gene therapy: promises and challenges. Gene Ther (2000) 1.65
Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. Biochemistry (1988) 1.51
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry (1982) 1.25
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J (2006) 1.20
Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. J Biol Chem (2001) 1.16
Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc Natl Acad Sci U S A (1997) 1.15
Liposomes for use in gene delivery. J Drug Deliv (2010) 1.15
Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum. Gene Ther (1998) 1.14
Progress and prospects: gene therapy clinical trials (part 1). Gene Ther (2007) 1.09
Chemical vectors for gene delivery: uptake and intracellular trafficking. Curr Opin Biotechnol (2010) 1.08
Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. Int J Pharm (2007) 1.02
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther (2007) 1.00
Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J Virol (1998) 0.99
Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog (1999) 0.98
Virosomes: cationic liposomes enhance retroviral transduction. Nat Biotechnol (1996) 0.96
Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm (2010) 0.95
Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectors. Gene Ther (1998) 0.94
Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophages. Hum Gene Ther (1996) 0.92
Biophysical and lipofection studies of DOTAP analogs. Biochim Biophys Acta (2000) 0.88
SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm (2011) 0.88
Association of glycosylphosphatidylinositol-anchored protein with retroviral particles. FASEB J (2008) 0.87
Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA. Mol Biotechnol (2008) 0.87
Rafts, anchors and viruses--a role for glycosylphosphatidylinositol anchored proteins in the modification of enveloped viruses and viral vectors. Virology (2008) 0.86
Nanoengineering artificial lipid envelopes around adenovirus by self-assembly. ACS Nano (2008) 0.84
Engineering of a stable retroviral gene delivery vector by directed evolution. Mol Ther (2007) 0.84
Rapid modification of retroviruses using lipid conjugates. Nanotechnology (2009) 0.84
Phase diagram of 1,2-dioleoylphosphatidylethanolamine (DOPE):water system at subzero temperatures and at low water contents. Biochim Biophys Acta (1999) 0.83
A top-down approach for construction of hybrid polymer-virus gene delivery vectors. J Control Release (2010) 0.82
Rescue of retroviral envelope fusion deficiencies by cationic liposomes. J Gene Med (2002) 0.81
Effect of serum on transfection by polyethylenimine/virus-like particle hybrid gene delivery vectors. Pharm Res (2010) 0.81
Mesomorphic complexes of DNA with the mixtures of a cationic surfactant and a neutral lipid. Langmuir (2005) 0.80
Cancer gene therapy clinical trials: lessons for the future. Br J Cancer (2001) 0.80
Gene therapy applied to treatment of HIV-1 infection. Lancet (1998) 0.78
Inactivation of murine leukaemia virus by exposure to visible light. Virology (2005) 0.77
Retargeting of viral vectors to the folate receptor endocytic pathway. J Control Release (2001) 0.77
Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres--a review. J Control Release (2012) 1.73
Microspheres for controlled release drug delivery. Expert Opin Biol Ther (2004) 1.52
A degradable polyethylenimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem (2003) 1.50
Acetylation of polyethylenimine enhances gene delivery via weakened polymer/DNA interactions. Biomacromolecules (2006) 1.43
PLG microsphere size controls drug release rate through several competing factors. Pharm Res (2003) 1.36
Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release (2002) 1.27
On the kinetics of polyplex endocytic trafficking: implications for gene delivery vector design. Mol Ther (2002) 1.24
Efficient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells. J Control Release (2009) 1.13
Uniform double-walled polymer microspheres of controllable shell thickness. J Control Release (2004) 1.08
Partial acetylation of polyethylenimine enhances in vitro gene delivery. Pharm Res (2004) 1.07
Microsphere size, precipitation kinetics and drug distribution control drug release from biodegradable polyanhydride microspheres. J Control Release (2004) 1.04
Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution. J Control Release (2005) 1.02
Macromolecule release from monodisperse PLG microspheres: control of release rates and investigation of release mechanism. J Pharm Sci (2007) 0.99
Cyclodextrin-polyethylenimine conjugates for targeted in vitro gene delivery. Biotechnol Bioeng (2005) 0.99
Monodisperse liquid-filled biodegradable microcapsules. Pharm Res (2007) 0.96
DNA nanoparticles encapsulated in 3D tissue-engineered scaffolds enhance osteogenic differentiation of mesenchymal stem cells. J Biomed Mater Res A (2008) 0.96
The effect of chitosan on the migration of neutrophil-like HL60 cells, mediated by IL-8. Biomaterials (2008) 0.90
HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization. Biomaterials (2008) 0.90
Three-month, zero-order piroxicam release from monodispersed double-walled microspheres of controlled shell thickness. J Biomed Mater Res A (2004) 0.90
In vitro degradation of polyanhydride/polyester core-shell double-wall microspheres. Int J Pharm (2005) 0.89
Mechanism of drug release from double-walled PDLLA(PLGA) microspheres. Biomaterials (2013) 0.89
Synergistic effects in gene delivery-a structure-activity approach to the optimisation of hybrid dendritic-lipidic transfection agents. Chem Commun (Camb) (2008) 0.89
Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy. J Control Release (2012) 0.88
Modelling intravascular delivery from drug-eluting stents with biodurable coating: investigation of anisotropic vascular drug diffusivity and arterial drug distribution. Comput Methods Biomech Biomed Engin (2012) 0.87
Hydrophobically modified dendrons: developing structure-activity relationships for DNA binding and gene transfection. Mol Pharm (2011) 0.86
Small-molecule release from poly(D,L-lactide)/poly(D,L-lactide-co-glycolide) composite microparticles. J Pharm Sci (2005) 0.85
Protein encapsulation in and release from monodisperse double-wall polymer microspheres. J Pharm Sci (2013) 0.84
Engineering of a stable retroviral gene delivery vector by directed evolution. Mol Ther (2007) 0.84
A top-down approach for construction of hybrid polymer-virus gene delivery vectors. J Control Release (2010) 0.82
Dependence of PEI and PAMAM Gene Delivery on Clathrin- and Caveolin-Dependent Trafficking Pathways. Pharm Res (2014) 0.82
Influence of particle size and antacid on release and stability of plasmid DNA from uniform PLGA microspheres. J Control Release (2007) 0.82
Controlling surface nano-structure using flow-limited field-injection electrostatic spraying (FFESS) of poly(D,L-lactide-co-glycolide). Biomaterials (2004) 0.81
Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials (2013) 0.81
Effect of serum on transfection by polyethylenimine/virus-like particle hybrid gene delivery vectors. Pharm Res (2010) 0.81
Biochemical investigation of active intracellular transport of polymeric gene-delivery vectors. J Pharm Sci (2008) 0.80
Timing is everything. Nat Mater (2004) 0.80
Dendrons with spermine surface groups as potential building blocks for nonviral vectors in gene therapy. Bioconjug Chem (2006) 0.79
Controlled protein release from monodisperse biodegradable double-wall microspheres of controllable shell thickness. J Control Release (2013) 0.79
Use of thermodynamic parameters for design of double-walled microsphere fabrication methods. Biomaterials (2006) 0.78
Pulsatile protein release from monodisperse liquid-core microcapsules of controllable shell thickness. Pharm Res (2014) 0.78
Degradable self-assembling dendrons for gene delivery: experimental and theoretical insights into the barriers to cellular uptake. J Am Chem Soc (2011) 0.77
Acid-Sensitive Magnetic Nanoparticles as Potential Drug Depots. AIChE J (2011) 0.76
The effects of PVP(Fe(III)) catalyst on polymer molecular weight and gene delivery via biodegradable cross-linked polyethylenimine. Pharm Res (2011) 0.75
Synergistic effects on gene delivery--co-formulation of small disulfide-linked dendritic polycations with Lipofectamine 2000. Org Biomol Chem (2009) 0.75